Target-Safety GNN on a Biomedical Knowledge Graph

Do the typed relationships in a public biomedical knowledge graph predict drug-safety endpoints for protein targets — beyond node popularity, and beyond target features that need no graph at all?

The operative word in the brief is whether. This is a feasibility question with an admissible negative answer, and the pipeline is built so it can return one.

The nine layers, and what fails at each →